Clinical Outcomes and Toxicity Profile of Cetuximab-Containing Regimen in Locoregional Recurrent and Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Institution Retrospective Audit
Indian Journal of Medical and Paediatric Oncology · 01.02.2026 · 47 (01) · A01-A58
DOI: 10.1055/s-0046-1818399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.02.2026. Verfasst von Siddhesh Rajendra Tryambake und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim and Objectives: To investigate the treatment outcomes of a regimen comprising cetuximab in groups of patients with locoregionally recurrent and metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Materials and Methods: Between January 2013 and May 2023, we included 100 patients with R/M SCCHN who were treated with cetuximab-based chemotherapy. Clinical outcomes, viz. OS, PFS, ORR, DCR, and toxicity profile were evaluated.
Results
Median age of study group was 56.5 (29–84). 85% were male. 13% had multiple comorbidities. 52% had metastatic disease, and 48% recurrent disease. 49% accounted for Ca oral cavity as the primary site, followed by less common sites. ECOG PS was 1 in 56%, 2 in 34%, and 3 in 10% of patients. Median duration of follow-up was 33.5 months (10–390). mOS was 19 months (95% CI: 17.1–20.9). 1 year OS rate was 77.9%, while 2-year OS rate was 33%. mPFS was 3 months (95% CI: 2.7–3.3). 3-month PFS rate was 34.7%, while 6-month PFS rate was 12.6%. 37% showed PR, 18% SD, and 45% PD as initial response. Thus, for the entire study population, ORR was 37% and DCR 55%. On subgroup analysis, mOS for patients with recurrent disease was 23 months (18.2–27.8), and 17 months (14.8–19.1) for patients in the metastatic stage ( p = 0.01). mPFS was 3 months in both the groups. Patients with recurrent disease showed better response rates with ORR of 43.8% and DCR of 60.5% as against ORR and DCR of 30.8 and 50% in metastatic setting, respectively. No patients died of severe adverse reactions during treatment. Grade III and above toxicities were noted in 27% showing rash, 12% diarrhea, 15% mucositis, 21% fatigue, and 5% febrile neutropenia.
Conclusion
When treated with a cetuximab-containing regimen, locoregional recurrence of SCCHN is associated with superior disease control and survival results compared to distant metastatic SCCHN. Publication History Article published online: 20 February 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Zitieren
APA
Tryambake, S. R., & Nirni, S. S. (2026). Clinical Outcomes and Toxicity Profile of Cetuximab-Containing Regimen in Locoregional Recurrent and Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Institution Retrospective Audit. Indian Journal of Medical and Paediatric Oncology, 47(01), A01-A58. https://doi.org/10.1055/s-0046-1818399
Vancouver
Tryambake SR, Nirni SS. Clinical Outcomes and Toxicity Profile of Cetuximab-Containing Regimen in Locoregional Recurrent and Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Institution Retrospective Audit. Indian Journal of Medical and Paediatric Oncology. 2026;47(01):A01-A58. doi:10.1055/s-0046-1818399
BibTeX
@article{Tryambake2026,
author = {Tryambake, Siddhesh Rajendra and Nirni, S. S.},
title = {Clinical Outcomes and Toxicity Profile of Cetuximab-Containing Regimen in Locoregional Recurrent and Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Institution Retrospective Audit},
journal = {Indian Journal of Medical and Paediatric Oncology},
year = {2026},
volume = {47},
number = {01},
pages = {A01--A58},
doi = {10.1055/s-0046-1818399}
}
EUVIMED